Tuesday , June 18 2019
Home / zimbabwe / Combined light and nanotechnology to prevent biofilm in medical implants

Combined light and nanotechnology to prevent biofilm in medical implants

Combined light and nanotechnology to prevent biofilm in medical implants

Surgical medical mesh, invented about 50 years ago, has become a key factor in the recovery process of damaged tissue surgery, the most common being hernia correction. When implanted in a patient's tissue, the flexible and compliant design of the mesh helps keep the muscles firm and allows the patient to recover much faster than conventional sowing and stitching.

However, implanting medical implants into the patient's body can lead to bacterial contamination during surgery and infectious biofilm formation on the surgical mesh surface. These biofilms act like impermeable coatings to prevent the antimicrobial agent from reaching and attacking the bacteria on the film to prevent infection. Thus, time-limited antibiotic therapy can fail for these super-resistant bacteria and the patient can end up with repetitive surgery that can lead to death. In fact, according to the European Antimicrobial Resistance Monitoring Network (EARS-Net), more than 30,000 deaths in Europe in 2015 were associated with antibiotic resistant bacterial infections.

In the past, several approaches have been tried to prevent implant contamination during surgery. Although post-operative aseptic tests have been established and performed to combat these antibiotic-resistant bacteria, no patients have yet completed the role of solving this problem.

In a recent study Nano letter Highlight in Nature Photonics, ICFO Researcher Ignacio de Miguel, Arantxa Albornoz, Professor of ICREA at ICFO Romain Quidant, Dr Irene Prieto, Dr. Vanesa Sanz, Dr. Christine Weis, and Dr. Pau Turon, major medical devices and pharmaceutical companies, We have devised a new technology that dramatically improves the performance of medical meshes for surgical implants.

ICFO and B. Braun Surgical's team of researchers have been working on a collaborative effort since 2012 to develop a feature-rich medical mesh. The surface of the mesh has been chemically modified to hold millions of gold nanoparticles. Why? Because gold nanoparticles have been proven to convert light very efficiently in very localized areas.

The technology of using gold nanoparticles in a light-to-heat conversion process has already been tested in cancer therapy in previous studies. In ICFO, this technique has been implemented in many previous studies supported by the Cellex Foundation, so the early charitable support for solving the ultimate problem has become another important example that leads to ultimate critical applications. Knowing that this particular case has more than 20 million cases of hernia per year worldwide, we believe that this method can reduce the cost of medical care for relapsing surgery while eliminating expensive, ineffective antibiotic therapies currently in operation.

Thus, through lab experiments and thorough procedures, millions of gold nanoparticles were coated on the surgical mesh and spread evenly over the entire structure. They tested the mesh to ensure long-term stability of the particles, non-decomposition of the material and non-release or release of the nanoparticles into the surrounding environment (flask). They were able to observe the homogeneous distribution of nanoparticles through the structure using a microscope scanning electron microscope.

Once the modified mesh is ready, the team S.aureus The bacteria were allowed to stand for 24 hours until a biofilm was formed on the surface. They then began to expose the mesh to short intense pulses of near-infrared light (800 nm) for 30 seconds to reach thermal equilibrium, repeating the break interval between each pulse 20 times in 4 seconds. They found the following facts. First, it was found that illuminating the mesh at a specific frequency would induce local surface plasmon resonance in the nanoparticles. In other words, it was a mode of efficiently converting light into heat while burning bacteria on the surface. Second, we used a fluorescence confocal microscope to determine how many bacteria died or were still alive. In the case of living bacteria, they observed that biofilm bacteria became planktonic cells, restoring susceptibility or weakness to antibiotic treatment and immune system responses. In the case of dead bacteria, as the amount of light transmitted to the surface of the mesh increases, the bacteria lose their adhesion and peel off from the surface. Third, we have confirmed that operation in the near infrared region is fully compatible with the in vivo environment, which means that such technology will not damage surrounding healthy tissue. Finally, they repeated the treatment and confirmed that repeated heating of the mesh did not affect its conversion efficiency capability.

"The results of this study opened the way to use plasmon nanotechnology to prevent the formation of bacterial biofilms on the surface of surgical implants," said ICREA Professor ICREA of Romain Quidant. It is important to emphasize that radical changes in the surgical procedure and recovery after patient replacement will mean recovery. "

"Our commitment to helping healthcare professionals to avoid hospital-acquired infections will allow us to develop new strategies for fighting bacteria and biofilms," said Dr. Pau Turon, head of research and development at B. Braun Surgical. We will expand that technology to other areas where biofilm should be avoided. "


References: Plasmon-based biofilm inhibition of surgical implants, Ignacio de Miguel, Irene Prieto, Arantxa Albornoz, Vanesa Sanz, Christine Weis, Pau Turón and Romain Quidant. Nano letter, 2019, 10.1021 / acs.nanolett.9b00187

About ICFO

The ICFO – Institute of Photonic Sciences was founded in 2002 by the Government of Catalonia and the Universitat Politècnica de Catalunya (UPC), both members of the board of directors, together with the Cellex and Mir-Puig Foundation, Located in the Mediterranean Technology Park, the institute now invites 400 people and is organized into 26 research groups from 60 state-of-the-art laboratories. The research line encompasses diverse areas where photonics plays a crucial role, focusing on basic and applied themes related to medicine and biology, advanced imaging technology, information technology, various environmental sensors, tunable and ultra-fast lasers, quantum science and related technologies . Researches on the properties and applications of nanomaterials such as photocells and graphene. In addition to the Severo Ochoa accreditation of the two countries, ICFOnians received 15 grants from ICREA and 35 from the European Research Council. ICFO is actively involved in the European Technological Platform Photonics21 and is also active in fostering entrepreneurial activity, creating spills, and creating collaboration and links between industry and ICFO researchers. To date, ICFO has helped found seven startup companies.

B. Introduction to BRAUN

With more than 63,000 employees in 64 countries, the B. Braun family business is one of the leading providers of medical market solutions worldwide and provides products and systems for anesthesia, intensive care, cardiology, in vitro blood treatment, and surgery to users and patients provide. , Or home care, as well as clinics and physician services. B. Braun promotes effective solutions to protect people's health and improve their lives in a constructive dialogue with customers and partners.

B. Braun Surgical is a subsidiary of the B. Braun Group in the Aesculap division. This division is divided into seven key indications: general open surgery, orthopedic arthroplasty, neurosurgery, laparoscopic surgery, interventional vascular diagnosis and treatment, degenerative spinal diseases and cardiac thoracic surgery. Since 1995, the Rubí-based factory has been the Center of Excellence for Suture Suture. In 2008, Rubí took on greater responsibilities and was appointed to the Center of Excellence of the Closure Technologies Strategic Business Unit of the Aesculap Division. B. Braun Spain is a reference center for the B. Braun Group and is responsible for research and development, manufacturing, quality control, regulatory affairs, strategic marketing and supply chain management worldwide.

In addition, B. Braun Surgical's research and development department collaborates with medical and scientific institutions to provide B. Braun's accumulated knowledge and experience to contribute to medical advancement. Some of the major hospitals in Catalonia have signed a partnership agreement with B. Braun to investigate surgical techniques that can improve and innovate closure techniques, tissue strength and alopecia.

In addition, B. Braun Surgical is working closely with top-level research organizations such as ICFO. – The Institute of Photonics, Universitat Politécnica de Catalunya, Universitat Autònoma de Barcelona, ​​Max Planck Polymer Research Institute, Leitat, Eurecat, Catalan Health Institute.

This story was posted on 2019-05-23. To contact the author, please use the contact details in the article.


We use a third-party service called Visqus to enable visitors to post comments on the website. Due to the amount of feedback, we do not review or review the comments posted.

Source link